Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway.

Journal of hepatology - 1 Aug 2011

Zhang Leiliang, Jilg Nikolaus, Shao Run-Xuan, Lin Wenyu, Fusco Dahlene N, Zhao Hong, Goto Kaku, Peng Lee F, Chen Wen-Chi, Chung Raymond T

Abstract excerpt

BACKGROUND & AIMS: The combination of pegylated interferon (IFN) α and ribavirin (RBV) is the standard therapy for patients with chronic HCV infection. However, it produces a sustained virologic response (SVR) in only half of the treated individuals and is associated with significant side effects...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Interferons
Share to Interleukins
Share to Janus Kinase 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinases

Share to Receptors, Interferon

Share to STAT Transcription Factors

Share to STAT1 Transcription Factor

Share to TYK2 Kinase

Source

Open in PubMed Open full text

Identifiers

PMID: 21147189
DOI: 10.1016/j.jhep.2010.11.019
PMCID: PMC3068235

Genes

STAT1
STAT2
JAK1
TYK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-21147189-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway.PMID 21147189Read ↗

IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice.Semantic proximity Read ↗

Novel type I interferon IL-28A suppresses hepatitis C viral RNA replicationSemantic proximity Read ↗

Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agentsSemantic proximity Read ↗

Role of IL28B for chronic hepatitis C treatment toward personalized medicine.Semantic proximity Read ↗

Distinct and overlapping genomic profiles and antiviral effects of Interferon‐λ and ‐α on HCV‐infected and noninfected hepatoma cellsSemantic proximity Read ↗

Kinetic differences in the induction of interferon stimulated genes by interferon-α and interleukin 28B are altered by infection with hepatitis C virusSemantic proximity Read ↗

Cellular Mechanism for Impaired Hepatitis C Virus Clearance by Interferon Associated with IFNL3 Gene Polymorphisms Relates to Intrahepatic Interferon-λ Expression.Semantic proximity Read ↗

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.Semantic proximity Read ↗

A single nucleotide polymorphism associated with hepatitis C virus infections located in the distal region of the IL28B promoter influences NF-κB-mediated gene transcription.Semantic proximity Read ↗

Immunomodulatory Function of Interleukin 28B during primary infection with cytomegalovirus.Semantic proximity Read ↗

The recent breakthroughs in the understanding of host genomics in hepatitis C.Semantic proximity Read ↗

IL28B in the era of direct-acting antivirals for hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.